Cover image for Chemistry and biological activities of ivermectin
Title:
Chemistry and biological activities of ivermectin
ISBN:
9781394168033

9781394168026
Physical Description:
1 online resource
Series:
Emerging trends in medicinal and pharmaceutical chemistry

Emerging trends in medicinal and pharmaceutical chemistry.
Contents:
Cover -- Title Page -- Copyright Page -- Contents -- Preface -- Chapter 1 Introduction to Ivermectin -- 1.1 Introduction -- 1.2 Sources and Synthesis -- 1.3 Pharmacological Potential of Ivermectin -- 1.3.1 Ivermectin in the Treatment of Cancer -- 1.3.1.1 Ovarian Cancer -- 1.3.1.2 Renal Cell Cancer -- 1.3.2 Ivermectin Against Viruses -- 1.3.3 Ivermectin in the Treatment of Bacterial Infections -- 1.4 Ivermectin's Beneficial Role in Cattle -- 1.5 Ivermectin in the Treatment of COVID-19 -- 1.5.1 Mode of Action -- 1.6 Toxicity of Ivermectin -- 1.6.1 Acute Toxicity -- 1.6.2 Developmental and Reproduction Toxicity -- 1.6.3 General and Safety Pharmacology -- 1.7 Conclusion -- References -- Chapter 2 Historical Background of and Synthetic Approaches to Ivermectin (IVM) and its Homologues -- 2.1 Introduction -- 2.1.1 Historical Background of Ivermectin -- 2.2 Synthetic Approaches Towards the Construction of IVM and Analogues -- 2.3 Biosynthesis -- 2.4 Chemical Synthetic Pathway -- 2.5 Crystal Structure -- 2.6 Conclusion and Outlook -- Acknowledgements -- References -- Chapter 3 Ivermectin as a Repurposed Drug for COVID-19 -- 3.1 Introduction -- 3.2 Symptoms of COVID-19 -- 3.3 Repurposing of the Drugs -- 3.4 Repurposed Drugs for COVID-19 -- 3.5 Repurposing of Ivermectin for COVID-19 -- 3.6 Proposed Possible Mechanism of Action -- 3.7 SARS COVID-19 Clinical Studies with Ivermectin -- 3.8 Conclusions -- 3.9 Acknowledgments -- References -- Chapter 4 Ivermectin as an Anti-Parasitic Agent -- Abbreviations -- 4.1 Introduction -- 4.2 Use of Ivermectin Against Various Human Parasitic Infections -- 4.2.1 Strongyloidiasis -- 4.2.2 Onchocerciasis -- 4.2.3 Lymphatic Filariasis -- 4.2.4 Loiasis -- 4.2.5 Scabies -- 4.2.6 Pediculosis -- 4.2.7 Mansonellosis -- 4.2.8 Ascariasis -- 4.2.9 Gnathostomiases -- 4.2.10 Leishmaniasis -- 4.2.11 Malaria.

4.3 Mode of Action Against Various Parasites -- 4.4 Conclusions -- 4.5 Acknowledgements -- References -- Chapter 5 Emerging Paradigm of Ivermectin and its Hybrids in Elimination of Malaria -- 5.1 Introduction -- 5.2 Malaria -- 5.2.1 World Malaria Report 2021 -- 5.2.2 Malaria in India: Statistics and Facts -- 5.2.3 Providing Malaria Treatment Despite All Odds -- 5.2.4 Meeting the Global Goal -- 5.2.5 Elimination of Malaria -- 5.2.6 Status of Anti-Malarial Drugs -- 5.3 Life Cycle of Malaria -- 5.4 Drug Against Hepatic Malarial Stage -- 5.5 About Ivermectin -- 5.5.1 Ivermectin Against Liver Cells of Malaria Parasite -- 5.6 Designing and Synthesis of Ivermectin Inhibitors -- 5.6.1 Hybrids of Ivermectin -- 5.7 Conclusions -- 5.8 Acknowledgments -- References -- Chapter 6 Ivermectin: A Potential Repurposed Anti-Cancer Therapeutic -- Abbreviations -- 6.1 Introduction -- 6.2 Mechanism of Anti-Carcinogenesis -- 6.3 Activation of Chloride Ion Channels -- 6.4 Anti-Mitotic Effect and Inhibition of Angiogenesis -- 6.5 Inhibition of Mitochondrial Respiration -- 6.6 Inhibitor of Cancer Stem Cells (CSCs) -- 6.7 Induction of Immunogenic Cell Death (ICD) -- 6.8 Epigenetic Modulator -- 6.9 Induction PAK1-Mediated Cytostatic Autophagy -- 6.10 Inhibition of P-glycoprotein (P-gp) -- 6.11 Inhibition of Yes-Associated Protein 1 (YAP1) -- 6.12 Inhibition of RNA Helicase -- 6.13 Caspase-Dependent Apoptosis -- 6.14 Activation of Transcription Factor E3 (TFE3) -- 6.15 Inhibition of Wnt-TCF Pathway Responses -- 6.16 Conclusions -- References -- Chapter 7 Ivermectin as an Anti-Inflammatory Agent -- 7.1 Introduction -- 7.2 Ant-Inflammatory Action of Ivermectin -- 7.3 Conclusions -- Acknowledgements -- References -- Chapter 8 Ivermectin: An Anthelminthic and Insecticide -- 8.1 Introduction -- 8.2 Ivermectin as an Anthelmintic -- 8.2.1 Mode of Action.

8.2.2 Ivermectin and Public Health -- 8.2.3 Challenges of Ivermectin Use as an Anthelminthic -- 8.3 Insecticidal Activity of Ivermectin -- 8.3.1 Mode of Action -- 8.3.2 Overview of Ivermectin as an Insecticide -- 8.3.3 Methods of Application to Animals and Plants -- 8.3.4 Disease Vector Control -- 8.3.5 Ivermectin Against Agricultural, Stored Grain Insect Pests and Other Insects -- 8.3.6 Ivermectin Usage in Livestock -- 8.3.7 Environmental Impact of Ivermectin -- Conclusions -- References -- Chapter 9 Potential Applications of Ivermectin (IVM) in Dermatology -- 9.1 Introduction -- 9.2 Mechanism of Action, Toxicity, and Side Effects of IVM -- 9.3 Motivational Approach of IVM in the Treatment of Skin -- 9.3.1 Anti-Bacterial Agent -- 9.3.2 Anti-Fungal Agent -- 9.3.3 Anti-Viral Agent -- 9.3.4 Anti-Protozoal Agent -- 9.4 Role of IVM with Good Anti-Parasitic Properties Against the Infection of Skin -- 9.4.1 Arthropods -- 9.4.2 Nematodes -- 9.5 Importance of IVM as an Anti-Cancer or Anti-Tumor Agent in Curing the Skin -- 9.6 Social Value of IVM in the Medical Care of Red Scrotum Syndrome (RSS) -- 9.7 Utility of IVM as an Anti-Inflammatory Drug in the Treatment of Skin-Related Issues -- 9.7.1 Allergy -- 9.7.2 Psoriasis or Crusted Scabies -- 9.7.3 Asthma -- 9.8 Conclusions -- Acknowledgements -- References -- Chapter 10 Antiviral Uses of Ivermectin -- 10.1 Introduction -- 10.2 Mechanism of Action of Ivermectin -- 10.3 Anti-Viral Effects Against Various DNA and RNA Viruses -- 10.3.1 RNA Viruses -- 10.3.1.1 COVID-19 -- 10.3.1.2 Zika Virus -- 10.3.1.3 Dengue Virus -- 10.3.1.4 Foot-and-Mouth Disease Virus -- 10.3.1.5 Hendra Virus -- 10.3.1.6 Newcastle Virus -- 10.3.1.7 Avian Influenza A Virus -- 10.3.1.8 Human Immunodeficiency Virus Type 1 -- 10.3.2 DNA Viruses -- 10.3.2.1 Equine Herpesvirus Type 1 (EHV-1) -- 10.3.2.2 Pseudorabies Virus (PRV).

10.3.2.3 BK Polyomavirus (BKPyV) -- 10.3.2.4 Porcine Circovirus 2 (PCV2) -- 10.4 Conclusion -- References -- Chapter 11 Toxicology, Safety, and Environmental Aspects of Ivermectin -- 11.1 Introduction -- 11.2 Ivermectin's Antiparasitic Activity -- 11.3 Pharmacology -- 11.4 Adverse Effects in Humans and Animals -- 11.5 Ivermectin and Ectoparasites -- 11.5.1 Scabies -- 11.5.2 Pediculosis -- 11.5.3 Strongyloidiasis -- 11.5.4 Onchocerciasis -- 11.5.5 Lymphatic Filariasis -- 11.5.6 Loasis -- 11.6 Environmental Impact and Biodegradation of Ivermectin -- 11.7 Conclusion -- References -- Index -- EULA.
Abstract:
Ivermectin (IVM) is a "wonder drug" containing a 16-membered macrocyclic lactone ring system in its structure and derived from the family of avermectins. It was isolated by the fermentation of the soil microorganism Streptomyces avermitilis by Satoshi Omura in 1960 and studied by William C. Campbell in 1981, which allowed for its treatment of onchocerciasis (River Blindness) in Africa. Both scientists subsequently received the 2015 Nobel Prize in Physiology or Medicine. It was approved by the FDA in 1997 for the treatment of Strongyloidiasis and crusted scabies in AIDS patients. After that, IVM has attracted the tremendous attention of the scientific community and has been used for diverse purposes, including as an inhibitor of the causative virus (SARS-CoV-2). The chief purpose of this volume is to focus on the chemistry and biological activities of ivermectin. The chapters have been arranged in a systematic manner, starting from the historical background and synthesis of IVM to the pharmacological and environmental aspects, followed by diverse applications. Although the usage of ivermectin for the treatment of COVID-19 remains under investigation and controversial, one of the chapters is dedicated to its use. The anti-parasitic, anti-malarial, anti-cancer, and anti-inflammatory activities of IVM are discussed in detail. The anthelminthic and insecticidal roles of IVM are briefly described and there are several cases of IVM in dermatology.
Local Note:
John Wiley and Sons
Holds:
Copies:

Available:*

Library
Material Type
Item Barcode
Shelf Number
Status
Item Holds
Searching...
E-Book 598579-1001 RM666 .I95 C44 2023
Searching...

On Order